Brawn Biotech Limited has announced the resignation of Director Mrs. Brij Bala Gupta from the company's Board of Directors, effective November 25, 2025. The pharmaceutical company provided additional details to BSE Limited on December 29, 2025, following an earlier communication dated December 22, 2025, in compliance with regulatory requirements.

Resignation Details

The resignation was formally submitted through a letter dated November 25, 2025, addressed to the Board of Directors. Mrs. Gupta's departure follows her decision to step down due to personal and professional commitments that prevent her from continuing in her directorial role.

Regulatory Compliance and Additional Disclosure

The company initially communicated the resignation to BSE Limited on December 22, 2025, but subsequently provided additional details on December 29, 2025, pursuant to BSE's request for complete documentation. The announcement was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III Part A Para 7C.

Brawn Biotech Limited acknowledged that it had inadvertently omitted to attach a copy of the resignation letter in its earlier communication, stating this was entirely unintentional. The company has now provided the complete resignation letter along with detailed reasons for the director's departure.

Director's Confirmation

Mrs. Brij Bala Gupta provided written confirmation to the company stating that there are no other material reasons for her resignation beyond those mentioned in her resignation letter. In her resignation letter, she expressed gratitude to the Board, management, and all stakeholders for the support extended during her tenure as Director.

The resignation letter specifically requested the Board to complete all necessary filings and formalities as required under regulatory provisions. Mrs. Gupta confirmed her resignation was due to pre-occupation and certain unavoidable circumstances that prevented her from continuing in her directorial capacity.

Company Information

Brawn Biotech Limited operates in the pharmaceutical sector with its registered office located at C-64, Lajpat Nagar-1, First Floor, New Delhi-110024. The company's manufacturing facility is situated at Plot No. 44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram-122001, Haryana. The company trades on BSE under scrip code 530207 with the symbol BRAWN.

Brawn Biotech Limited , a pharmaceutical company, has announced its financial results for the second quarter ended September 30, 2025. The company reported a net loss of Rs. 7.44 lacs for the quarter, with revenue from operations standing at Rs. 797.00 lacs.

Key Financial Highlights

Financial Performance Analysis

Brawn Biotech's revenue from operations showed a significant improvement compared to both the previous quarter and the same quarter last year. However, despite the increase in revenue, the company reported a net loss for the quarter.

Operational Highlights

• The Board of Directors approved the unaudited financial results in their meeting held on November 14, 2025.
• The company's total expenses for the quarter stood at Rs. 798.98 lacs, showing an increase from the previous quarter.
• Other income for the quarter was Rs. 9.12 lacs, remaining relatively stable compared to the previous quarter.

Balance Sheet Overview

As of September 30, 2025, Brawn Biotech reported:

• Total assets of Rs. 2,215.67 lacs
• Total equity of Rs. 370.52 lacs
• Current liabilities of Rs. 1,885.15 lacs

Auditor's Review

Rajiv Udai & Associates, Chartered Accountants, conducted a limited review of the financial results. They stated that nothing has come to their attention that causes them to believe that the financial results do not present a true and fair view in accordance with applicable accounting standards and other recognized accounting practices and policies.

Investors and stakeholders are advised to consider these results in the context of overall market conditions and the pharmaceutical industry's performance.